← Back

Aspire BioPharma, Inc.

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company that develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers a sublingual aspirin product that is soluble, pH-neutral, and fast-acting, targeting cardiology emergencies and pain management. The company is also developing sublingual formulations for products such as melatonin sleep aids, vitamins D, E, and K, testosterone, and semaglutide, as well as anti-nausea, anti-psychotic, ED, seizure, and other drug classes, and caffeine products including a single-dose sublingual pre-workout supplement. Founded in 2021, it is headquartered in Estero, Florida.

Country
Price · split & dividend adjusted
News & notes moving ASBP
ASBP

Aspire Biopharma Completes $30 Million Acquisition of Dura Driver Control Systems

Aspire Biopharma Holdings Inc. completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market. The deal gives Aspire 100% ownership of DCS, a tier-one automotive supplier of electronic driver controls, which is now a wholly owned subsidiary. Aspire paid about $30 million in cash and also entered into a $22.5 million senior secured revolving credit facility to help finance the transaction. DCS generated $209.5 million in audited revenue and $22.3 million in adjusted EBITDA in 2025, and for the first six months of 2026 it posted unaudited revenue of about $103.9 million and adjusted EBITDA of $10.5 million. CEO Kraig Higginson said the acquisition is a cash-flow-positive milestone that structurally enhances Aspire's valuation and adds high-volume revenue streams.
Benzinga·39dRead more →
ASBP

Aspire Biopharma's BUZZ BOMB Caffeine Stick Packs Launch on Amazon

Aspire Biopharma Holdings' subsidiary Buzz Bomb Caffeine Company has launched its BUZZ BOMB 50-milligram caffeine stick packs on Amazon's U.S. store. The waterless, rapid-dissolve powder is designed for sublingual delivery, offering a portable energy alternative to traditional drinks and pills. The product is available in Variety Pack, Mixed Berry, and Mango flavors in 20-packet boxes. CEO Kraig Higginson stated the Amazon launch allows the brand to reach a health-conscious audience through a trusted marketplace.
ACCESS Newswire·86dRead more →
ASBP

Aspire Biopharma to Present at Life Sciences Investor Forum on June 25th

Aspire Biopharma Holdings, Inc. will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026 at 2:00 pm ET. The event is a live, interactive online forum where investors and industry professionals can submit questions to management in real time, with one-on-one meetings available on June 24th and 25th. A replay of the webcast will be available after the conference. Aspire Biopharma highlighted its lead drug candidate, a high-dose aspirin prescription product that demonstrated dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in a trial, along with its new caffeine product BUZZ BOMB which generated commercial revenue in 2025 and launched a new e-commerce website, packaging, and product in January 2026. The company also noted a proposed acquisition of Dura Driver Control Systems, a global automotive supplier with over $200 million in 2025 unaudited revenue, expected to close in the third quarter.
GlobeNewswire·93dRead more →